Cite
House of Lords Revisits ‘Biogen’ Insufficiency; Novartis' Fluvastatin Patent Obvious; High Court Finds Patent for Slow Release Formulation Valid but not Infringed
MLA
James Armstrong, et al. “House of Lords Revisits ‘Biogen’ Insufficiency; Novartis’ Fluvastatin Patent Obvious; High Court Finds Patent for Slow Release Formulation Valid but Not Infringed.” Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector, vol. 6, May 2009, pp. 264–71. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........1830d76c05b7b8fb00640d8e915dfd5a&authtype=sso&custid=ns315887.
APA
James Armstrong, Rebecca Singleton, Jade MacIntyre, & Michael Burdon. (2009). House of Lords Revisits ‘Biogen’ Insufficiency; Novartis’ Fluvastatin Patent Obvious; High Court Finds Patent for Slow Release Formulation Valid but not Infringed. Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector, 6, 264–271.
Chicago
James Armstrong, Rebecca Singleton, Jade MacIntyre, and Michael Burdon. 2009. “House of Lords Revisits ‘Biogen’ Insufficiency; Novartis’ Fluvastatin Patent Obvious; High Court Finds Patent for Slow Release Formulation Valid but Not Infringed.” Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 6 (May): 264–71. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........1830d76c05b7b8fb00640d8e915dfd5a&authtype=sso&custid=ns315887.